SkinBioTherapeutics (LON:SBTX) Shares Down 6.5% – Should You Sell?

SkinBioTherapeutics plc (LON:SBTX)’s share price dropped 6.5% on Monday . The stock traded as low as GBX 10.61 and last traded at GBX 10.75. Approximately 392,247 shares were traded during mid-day trading, a decline of 87% from the average session volume of 2,906,237 shares. The stock had previously closed at GBX 11.50.

SkinBioTherapeutics Price Performance

The stock’s fifty day moving average price is GBX 10.48 and its 200-day moving average price is GBX 11. The firm has a market cap of £27.86 million, a price-to-earnings ratio of -67.19 and a beta of 0.11. The company has a current ratio of 6.14, a quick ratio of 10.01 and a debt-to-equity ratio of 11.77.

SkinBioTherapeutics (LON:SBTX) last released its quarterly earnings data on Monday, June 8th. The company reported GBX (0.31) EPS for the quarter. The business had revenue of GBX 217 million during the quarter. SkinBioTherapeutics had a negative net margin of 8.73% and a negative return on equity of 5.25%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.